The U.S. Food and Drug Administration (FDA) has issued warnings to 30 companies regarding the misleading marketing of compounded GLP-1 medications, reiterating that these drugs are not FDA-approved. Hims & Hers Health (HIMS) and its telehealth industry peers are closely monitoring the situation.